How Long Does Emgality Stay in the Body After the Last Dose?
Emgality (galcanezumab), a monoclonal antibody for migraine prevention, has a half-life of about 27 days in the body.[1] This means it takes roughly 27 days for half the drug to be eliminated after your last injection. Full clearance typically occurs after 4-5 half-lives, or around 4-5 months, though levels drop significantly sooner—below 50% after one month and near undetectable after 3 months for most patients.[2]
Blood concentrations decline gradually due to its large size and slow breakdown via proteolytic degradation, not kidney or liver clearance.[1][3]
When Do Migraine Effects Wear Off After Stopping?
Protective effects against migraines often last 3-6 months post-discontinuation, even as drug levels fall.[4] In clinical studies, some patients retained reduced migraine days for up to 6 months after stopping, linked to the drug's prolonged receptor binding on CGRP pathways.[2][5] Individual response varies based on dose history and metabolism.
Factors Affecting Clearance Time
- Body weight and age: Higher weight or older age can slightly prolong half-life (up to 30 days).[1]
- Kidney/liver function: Minimal impact since it's not cleared by these organs.[3]
- Multiple doses: Steady-state levels from monthly injections mean higher initial concentrations, extending time to full elimination.[2]
No drug interactions notably alter its half-life.[1]
What If You Need to Stop for Surgery or Pregnancy?
Guidelines recommend stopping Emgality 4-6 months before planned pregnancy due to its long half-life and limited data in pregnancy.[6] For surgery, no specific hold time exists, but its low bleeding risk means continuation is often fine—discuss with your doctor.[3] Trace amounts may persist up to 9 months in rare cases.[2]
Testing for Emgality in Your System
Routine blood tests don't typically check for it, but specialized assays detect levels for months. It's not known to cause false positives on standard drug screens.[1]
[1]: Emgality Prescribing Information (FDA)
[2]: Lilly Clinical Pharmacology Data
[3]: Drugs.com - Galcanezumab Pharmacokinetics
[4]: NEJM Study on CGRP Monoclonal Antibodies
[5]: Headache Journal Review on Discontinuation
[6]: ACOG Guidelines on Migraine Meds in Pregnancy